[
    {
        "ExclusionCriteria": "* Active untreated brain metastases.\n* Patient has any of the following:\n* Uncontrolled intercurrent illness including, but not limited to, poorly controlled hypertension or diabetes, or ongoing active infection requiring systemic therapy.\n* Patients with primary refractory EOC defined as patients who do not respond to their first platinum-containing regimen or who relapse less than 6 months after completion of that first platinum-containing regimen\n* Psychiatric illness that would limit compliance with study requirements.\n* Treatment with any of the following prior to the first dose of NX-1607: CPI (anti-PD-1, PD-L1, cytotoxic T-lymphocyte-associated protein 4, etc) within 3 weeks; autologous or allogeneic stem cell transplant within 100 days; prior systemic cancer therapy within 3 weeks or 5 half-lives (whichever is shorter) (unless otherwise specified) (including hormonal therapy except for hormonal prophylaxis for a prior malignancy); prior radiotherapy within 2 weeks; prior systemic therapy with nitrosoureas, antibody-drug conjugate, or radio-immuno-conjugate therapy within 6 weeks; use of strong or moderate CYP3A4 inducers or inhibitors within 14 days or 7 days, respectively, or 5 half-lives (whichever is longer)\n* History of CAR-T therapy within 30 days prior to the first dose of NX-1607.\n* Toxicities from previous anti-cancer therapies that have not resolved to baseline levels or to Grade 1 or less except for Grade 2 alopecia and Grade 2 peripheral neuropathy or patients receiving endocrine replacement therapy\n* Patients who experienced Grade 3 or higher irAEs with prior immunotherapy.\n* History of uveitis, or an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.\n* Unable to swallow capsules or has malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction likely to interfere with the delivery, absorption, or metabolism of NX-1607.\n* Known allergies, hypersensitivity, or intolerance to components of NX-1607.\n* Pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 6 months after the last dose of NX-1607.\n* Patient is a man who plans to father a child while enrolled in this study or within 3 months after the last dose of NX-1607 and, as applicable, within 6 months after the last dose of paclitaxel.\n* Patient has had major surgery (e.g., requiring general anesthesia) within 4 weeks before the planned first dose of NX-1607, or will not have fully recovered from surgery, or has surgery planned during the time the patient is expected to participate in the study or within 4 weeks after the last dose of NX-1607. Note: Patients with minor planned surgical procedures to be conducted under local anesthesia may participate.\n* Vaccinated with a live vaccine within 28 days (with the exception of the annual inactivated influenza vaccine) or COVID-19 vaccination within 14 days prior to the first dose of NX-1607.\n* Active known second malignancy with the exception of any of the following:\n\n  * Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer.\n  * Adequately treated Stage I cancer from which the patient is currently in remission and has been in remission for \u2265 2 years.\n  * Low-risk prostate cancer with Gleason score \\< 7 and PSA \\< 10 ng/mL.\n  * Any other cancer from which the patient has been disease-free for \u2265 2 years.\n* Infection with human immunodeficiency virus (HIV)-1 or HIV-2. Exception: Patients with well controlled HIV (e.g., CD4 \\> 350/mm3 and undetectable viral load) are eligible.\n* Current active hepatitis, including hepatitis A (hepatitis A virus immunoglobulin M \\[IgM\\] positive), hepatitis B (hepatitis B virus \\[HBV\\] surface antigen positive), or hepatitis C (hepatitis C virus \\[HCV\\] antibody positive, confirmed by HCV RNA). Patients with HCV with undetectable virus after treatment are eligible. Patients with prior exposure to HBV may be entered if quantitative PCR is negative.\n* Use of systemic corticosteroids (\\> 20 mg prednisone or equivalent) within 15 days (except for prophylaxis for radio diagnostic contrast reactions and/or prophylaxis for patients receiving paclitaxel), or other immunosuppressive drugs within 30 days, prior to the first dose of NX-1607.\n* Use of biotin (i.e., Vitamin B7) or supplements containing biotin higher than the daily adequate intake of 30 \u00b5g \\[NIH 2020\\] (Note: Patients who switch from a high dose to a dose of 30 \u00b5g/day or less at least 1 day prior to Screening assessments are eligible for study entry).\n* Receipt of an IP or has been treated with an investigational device within 3 weeks or 5 half-lives (whichever is shorter) prior to the first dose of NX-1607.\n* Any of the following within 6 months prior to the first dose of NX-1607 or ongoing:\n\n  * Myocardial infarction\n  * Unstable angina\n  * Unstable symptomatic ischemic heart disease\n  * New York Heart Association Class III or IV heart failure\n  * Thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events)\n  * Any other significant cardiac condition (e.g., pericardial effusion, restrictive cardiomyopathy, severe untreated valvular stenosis, or severe congenital heart disease)\n  * Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating Investigator in consultation with the Medical Monitor.",
        "NCTId": "NCT05107674"
    },
    {
        "ExclusionCriteria": "1. Systemic therapeutic radiopharmaceutical within 6 months prior to enrollment into this study.\n2. Contraindications to or inability to perform the required imaging procedures in this study (e.g., inability to lay flat during scan time)\n3. Uncontrolled brain metastasis, including but not limited to the need for treatment with steroids, surgery or radiation therapy.\n4. Anticancer therapy (including investigational agents) or external beam radiation therapy within 14 days of the dosing of \\[111In\\]-FPI-1547\n5. Has known additional malignancy that is progressing or has required active treatment within the past 3 years. Patients with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ (e.g., breast cancer, cervical cancer, prostate) that have undergone potentially curative therapy are not excluded.\n6. Residual CTCAE \u2265 Grade 2 side effects of prior therapy, with the exception of residual grade 2 alopecia.\n7. Prior organ transplantation, including stem cell transplantation.\n8. Any prior treatment with nitrosoureas or actinomycin-D.\n9. Clinically relevant levels of protein in the urine\n10. Known or suspected allergies or contraindications to the Investigational Products or any component of the investigational drug formulation.\n11. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, diabetes, or psychiatric illness/social situations that would limit compliance with study requirements.\n12. Received \\> 20 Gy prior radiation to large areas of the bone marrow",
        "NCTId": "NCT03746431"
    },
    {
        "ExclusionCriteria": "1. Patient has cardiac conditions as listed in the protocol.\n2. Patient has blood pressure (BP) \\>140/90 mmHg.\n3. Patient is pregnant or lactating.\n4. Patient has known untreated, active or uncontrolled brain metastases.\n5. Patient with leptomeningeal disease.\n6. Patient has a known additional malignancy that was progressing or required active treatment within 2 years prior to the first dose of study medication.\n7. Patient has a history of bowel obstruction, including sub-occlusive disease, related to the underlying disease or history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess.\n8. Patient has an active infection requiring IV systemic therapy.\n9. Patient has known hypersensitivity to any components of any study drug or any of its excipients that, in the opinion of the investigator, suggests a high risk for a severe hypersensitivity reaction while on treatment.\n10. Patient has a known clinically significant bleeding disorder.\n11. Patient is currently using oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes for which the dose has not been stable for \\>14 days prior to C1D1.\n12. Patient had hemoptysis \\>2.5 mL within 8 weeks prior to C1D1 or serious bleeding from another site within this time frame.\n13. Patient had a major surgical procedure, or significant traumatic injury within 28 days prior to C1D1.\n14. Patient has an uncontrolled seizure disorder or active neurologic disease.\n15. Patient has a cardiac aneurysm.\n16. Patient has a known psychiatric disorder, substance abuse disorder, or geographical travel limitations that in the opinion of the investigator would interfere with patient's ability to cooperate with the requirements of the study.\n17. Patient has a history or current evidence of any condition, therapy, or laboratory abnormality that may confound the results of the study, interfere with the patient's participation for the full duration of the study, or indicates a condition for which study participation is not in the best interest of the patient, in the opinion of the investigator.\n\n    Cohort A1 and Cohort A2 - CRC only:\n18. Patient has known microsatellite instability-high status.\n\n    Cohort A2 - CRC (navicixizumab + irinotecan) only:\n19. Patient is on dialysis.\n20. Patient has received hepatic intra-arterial chemotherapy.\n\n    Cohort B1 - Gastric/GEJ cancer only:\n21. Patient has experienced weight loss \\>10% over 2 months prior to first dose of study treatment.\n22. Patient has definitive pathologically confirmed HER2 positive metastatic gastric or GEJ adenocarcinoma.\n23. Patient has pre-existing Grade \u22652 peripheral neuropathy, according to CTCAE v5.0.\n\n    Cohort C2 - TNBC (navicixizumab + paclitaxel) only\n24. Patient has pre-existing Grade \u22652 peripheral neuropathy, according to CTCAE v5.0.\n\n    Cohort D1 - Ovarian cancer only:\n25. Patient has non-epithelial ovarian carcinoma.\n26. Patient has ovarian tumors with low malignant potential (ie, borderline tumors).",
        "NCTId": "NCT05453825"
    },
    {
        "ExclusionCriteria": "(exclusion criteria not marked) Key Inclusion Criteria\n\n* Life expectancy \u226512 weeks.\n* Patients must have measurable disease per RECIST 1.1.\n* Part A-1 cohorts:\n* Must have exhausted all standard treatment options, including appropriate targeted therapies; or patients for which no standard therapy is considered appropriate\n* Patients with advanced, histologically confirmed urothelial (transitional cell) carcinoma that recurred after or has been refractory to prior therapy (fresh tumor biopsy or an archived sample must be submitted); or\n* Patients with advanced, histologically confirmed pancreatic, breast, non-small-cell lung cancer (NSCLC), gastric, esophageal, head and neck, or ovarian tumors that recurred after or has been refractory to prior therapy (fresh tumor biopsy or an archived sample testing for Nectin-4 expression).\n* Part A-2:\n* Must have exhausted all standard treatment options, including appropriate targeted therapies; or patients for which no standard therapy is considered appropriate\n* Patients with advanced, histologically confirmed urothelial (transitional cell) carcinoma that have progressed following prior therapy\n* Cohort B-1: Histologically documented urothelial carcinoma, previously treated with enfortumab vedotin (EV). Patients with resectable, locally advanced urothelial carcinoma are ineligible. Must have had progression or recurrence of urothelial cancer during or following receipt of most recent therapy.\n* Cohort B-2 and B-3: Histologically documented urothelial carcinoma, not previously treated with enfortumab vedotin (EV). Patients with resectable, locally advanced urothelial carcinoma are ineligible. Must have had progression or recurrence of urothelial cancer during or following receipt of most recent therapy.\n* Cohort B-4: Patients with histologically confirmed non-mucinous epithelial ovarian, fallopian tube, or primary peritoneal cancer that is Stage III or IV according to the International Federation of Gynecology and Obstetrics (FIGO) or tumor, node and metastasis staging criteria that have progressed following prior therapy.\n* Cohort B-5: Patients with triple-negative breast cancer confirmed negative for estrogen receptor (ER) and progesterone receptor (PR) and negative for human epidermal growth factor receptor 2 (HER2) (i.e., triple-negative) that have progressed following prior therapy.\n* Cohort B-6: Patients with histologically confirmed non-small cell lung cancer (NSCLC) with no actionable mutations, such as Epidermal Growth Factor Receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) fusion oncogene, or ROS1 that have progressed following prior therapy.\n* Cohort B-7: Locally advanced or metastatic, histologically confirmed urothelial (transitional cell) carcinoma, ineligible for cisplatin, no prior systemic anticancer treatment for advanced urothelial carcinoma.\n* Cohort C renal insufficiency cohort: Patients with histologically documented urothelial carcinoma, ovarian, triple negative breast, or non-small cell lung cancer that have been previously treated with a locally approved therapy.\n\nKey Exclusion Criteria (all patients):\n\n* Clinically relevant troponin elevation\n* Uncontrolled diabetes\n* Known active or untreated CNS and/or carcinomatous meningitis\n* Grade \u22652 peripheral neuropathy\n* Active keratitis or corneal ulcerations\n* Patients with uncontrolled hypertension\n* History of another malignancy within 3 years before first dose of BT8009 or residual disease from a previously diagnosed malignancy (with some exceptions).\n* Active systemic infection requiring therapy, or fever within the last 14 days prior to first dose of BT8009.\n* Prior Stevens-Johnson syndrome/toxic epidermal necrolysis on any MMAE-conjugated drug\n* Parts A-2 and B-7 Pembrolizumab Combination Cohorts:\n* Prior organ transplant (including allogeneic)\n* Diagnosis of clinically relevant immunodeficiency\n* History of interstitial lung disease\n* Parts B-2 and B-3: Prior treatment with enfortumab vedotin Other protocol-defined Inclusion/Exclusion criteria may apply",
        "NCTId": "NCT04561362"
    },
    {
        "ExclusionCriteria": "* Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 4 months after the final dose of tobemstomig or pembrolizumab, and 6 months after the final dose of nab-paclitaxel\n* Poor venous access\n* History of malignancy within 5 years prior to consent, except for the cancer under investigation in this study and malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate \\>90%), such as adequately treated carcinoma in situ of the cervix, nonmelanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer\n* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases\n* History of leptomeningeal disease\n* Pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)\n* Hypercalcemia or hypercalcemia that is symptomatic\n* Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis (granulomatosis with polyangiitis), Sj\u00f6gren syndrome, Guillain-Barr\u00e9 syndrome, or multiple sclerosis\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted\n* Active tuberculosis (TB)\n* Significant cardiovascular/cerebrovascular disease within 3 months prior to consent\n* History or presence of an abnormal ECG that is deemed clinically significant\n* History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias such as structural heart disease (e.g., severe left ventricular systolic dysfunction, left ventricular hypertrophy), coronary heart disease (symptomatic or with ischemia demonstrated by diagnostic testing), clinically significant electrolyte abnormalities (e.g., hypokalemia, hypomagnesemia, hypocalcemia), or family history of sudden unexplained death or long QT syndrome\n* Major surgical procedure within 4 weeks prior to initiation of study treatment\n* Treatment with therapeutic oral or IV antimicrobials (anti-bacterial, anti-fungal, antiviral, anti-parasitic) within 1 week prior to initiation of study treatment\n* Prior allogeneic stem cell or solid organ transplantation\n* Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the participant at high risk from treatment complications\n* Treatment with a live, attenuated vaccine within 28 days prior to initiation of study treatment\n* Treatment with investigational therapy within 28 days prior to initiation of study treatment\n* Prior treatment with CD137 agonists or anti-CTLA therapeutic antibodies or an anti-LAG3 agent\n* Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and IL-2) within 4 weeks or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study treatment\n* Treatment with systemic corticosteroids or other systemic immunosuppressive medications (including, but not limited to, prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF agents) within 2 weeks prior to initiation of study treatment\n* History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins\n* Known hypersensitivity to Chinese hamster ovary cell products or to any component of the tobemstomig or pembrolizumab formulation\n* Known allergy or hypersensitivity to any component of the to nab-paclitaxel formulation",
        "NCTId": "NCT05852691"
    },
    {
        "ExclusionCriteria": "* Impaired cardiac function or clinically significant cardiac disease.\n* Use of agents known to prolong the QT interval unless they can be permanently discontinued for the duration of study.\n* History of severe hypersensitivity reactions to any ingredient of study drug(s) and other mAbs and/or their excipients.\n* Active, known or suspected autoimmune disease. Patients with vitiligo, type I diabetes, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment or conditions not expected to recur may be considered. Patients previously exposed to anti-PD-1/PD-L1 treatment who are adequately treated for skin rash or with replacement therapy for endocrinopathies should not be excluded.\n* Any evidence of interstitial lung disease (ILD) or pneumonitis, or a prior history of ILD or non-infectious pneumonitis requiring high-dose glucocorticoids.\n* Patients who discontinued prior anti-PD-(L)1 therapy due to an anti-PD-(L)1-related toxicity (applicable to the KFA115 in combination with pembrolizumab treatment arms).\n* Patients with symptomatic peripheral neuropathy limiting instrumental activities of daily living.\n\nOther protocol-defined inclusion/exclusion criteria may apply",
        "NCTId": "NCT05544929"
    },
    {
        "ExclusionCriteria": "* For Dose Expansion only:\n\n  * Participants with HCC, pancreatic adenocarcinoma, or MSS-CRC having prior exposure to a prior PD-1/PD-L1 antagonist in any line of therapy.\n  * Participants (except for participants with urothelial cancer or HNSCC) who have had prior exposure to immunotherapies as listed in the protocol.\n* Has received anticancer therapy including chemotherapy, immunotherapy, radiation therapy, biologic, herbal therapy, or any investigational therapy within a period of 5 half-lives or 28 days (whichever is shorter), prior to the first dose of the study drug.\n* Participant has unresolved AEs \\> Grade 1 from prior anticancer therapy except for alopecia.\n* Has a history of primary immunodeficiency, bone marrow transplantation, solid organ transplantation, or previous clinical diagnosis of tuberculosis.\n* Has a known uncontrolled metastases to the central nervous system (with certain exceptions).\n* Current or prior use of immunosuppressive medication within 14 days prior to the first dose of the study drug.\n* Has clinically significant uncontrolled condition(s).\n* History of inflammatory bowel disease, interstitial lung disease or pneumonitis, myocarditis, Stevens-Johnson syndrome, toxic epidermal necrolysis or drug reaction with eosinophilia and systemic symptoms (DRESS).\n* Live vaccine administration \\<= 28 days prior to the first dose of study drug.",
        "NCTId": "NCT03821935"
    },
    {
        "ExclusionCriteria": "* HER2-positive breast cancer by ASCO/CAP guidelines (HER2 IHC 3+ or \u2265 2.2 HER2/CEP17 ratio by FISH)\n* Inflammatory (cT4d) breast cancer\n* Metastatic breast cancer (M1)\n* Contraindication(s) to breast-conserving therapy or mastectomy\n* Contraindication to radiation therapy including: prior ipsilateral breast or mantle RT, active scleroderma, systemic lupus erythematosis and pregnancy.\n\n  --Note: All cardiac implantable electronic devices are permitted, provided that methods to assess radiation doses and minimize damage to the devices during RT is planned, per institutional guidelines.\n* Prior ipsilateral breast, chest wall or thoracic radiotherapy\n* Prior ipsilateral invasive breast cancer, contralateral breast cancer or a known additional, invasive malignancy that is progressing or required active treatment in the last 5 years.\n\n  --Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or cervical carcinoma in situ that has undergone potentially curative therapy and a previous diagnosis of ductal carcinoma in situ are not excluded.\n* Has a known history of active tuberculosis (Bacillus tuberculosis\n* Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).\n* Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to randomization.\n\n  --Note: Participants must have recovered from all AEs due to previous therapies to \u2264 Grade 1 or baseline. Participants with \u2264 Grade 2 neuropathy may be eligible. If participant received major surgery, she/he must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment.\n* Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.\n* Has known severe hypersensitivity (\u2265Grade 3) to pembrolizumab and/or any of its excipients.\n* Participants with active, known or suspected autoimmune disease. Participants with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n* Known history of Human Immunodeficiency Virus (HIV). Note: No HIV testing is required unless mandated by local health authorities.\n* Known active Hepatitis B (defined as hepatitis B surface antigen \\[HBsAg\\] reactive) or known active hepatitis C virus (defined as HCV RNA \\[qualitative\\] is detected). Note: Testing for hepatitis B or hepatitis C is not required, unless mandated by local health authorities or institutional guidelines.\n* Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Gu\u00e9rin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g. FluMist\u00ae) are live attenuated vaccines and are not allowed.\n* Has had an allogenic tissue/solid organ transplant\n* A WOCBP who has a positive urine pregnancy test within 72 hours before the first dose of study treatment (see Appendix A). If the urine test cannot be confirmed as negative, a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.\n* Prohibited Treatments and/or Therapies:Use of immunosuppressants and/or systemic corticosteroids is exclusionary, except the following in the absence of active autoimmune disease:\n\n  * As premedication for chemotherapy\n  * For the prevention of nausea in the three days following chemotherapy\n  * Participants are permitted the use of corticosteroids with minimal systemic absorption (e.g. topical, ocular, intra-articular, intranasal and inhaled)\n  * Systemic corticosteroids at physiologic doses \u2264 10 mg/day of prednisone or equivalent permitted\n  * Adrenal replacement steroid doses including doses \\>10 mg daily prednisone is permitted\n  * A brief (less than 3 weeks) course of corticosteroids for prophylaxis (e.g. CT scan premedication against contrast dye allergy) or for treatment of non-autoimmune conditions (e.g. delayed-type hypersensitivity reaction caused by a contact allergen is permitted (used in the management of cancer or non-cancer-related illnesses). However, use of corticosteroids is allowed for the treatment of immune-related Adverse Events (irAEs), or adrenal insufficiency.",
        "NCTId": "NCT04443348"
    },
    {
        "ExclusionCriteria": "* Prior treatment with an Antibody Drug Conjugate (ADC) containing an auristatin payload. Prior treatment with another ADC containing other payloads is allowed.\n* Major surgery within 28 days of starting study treatment, systemic anticancer therapy within the time period of 28 days or 5 half-lives of the prior therapy before starting study treatment (14 days or 5 half-lives for small molecule targeted therapy), whichever is less, or palliative radiation therapy within 14 days of starting study treatment.\n* Diagnosis of additional malignancy that required active treatment (including surgery, systemic therapy, and radiation) within 2 years prior to screening, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or of the cervix.\n* Untreated CNS metastases (including new and progressive brain metastases), history of leptomeningeal metastasis or carcinomatous meningitis.\n\n  1. Participants are eligible if CNS metastases are adequately treated, and participants are neurologically stable for at least 2 weeks prior to enrollment.\n  2. In addition, participants must be either off corticosteroids, or on a stable/decreasing dose of \u2264 10 mg daily prednisone (or equivalent). Anticonvulsants are allowed except for those drugs associated with liver toxicity\n  3. Participants may be eligible if CNS lesions are asymptomatic, equivocal for metastases or do not require specific therapy in the opinion of the investigator\n* Prior B7-H4 targeted treatment.\n* History of cirrhosis, hepatic fibrosis, esophageal or gastric varices, or other clinically significant liver diseases.\n* Current severe, uncontrolled systemic disease (e.g. clinically significant cardiovascular, pulmonary, or metabolic disease) or intercurrent illness that could increase the risk of serious adverse events (SAEs) or interfere with per-protocol evaluations, in the judgment of either the Sponsor or the Investigator.\n* Clinically significant cardiovascular disease",
        "NCTId": "NCT05377996"
    },
    {
        "ExclusionCriteria": "* Individual with known or suspected uncontrolled central nervous system (CNS) metastases\n* Individual with history of carcinomatous meningitis\n* Individual with active uncontrolled systemic bacterial, viral, fungal, or parasitic infection\n* Individual with evidence of corneal keratopathy or history of corneal transplant\n* Any serious unresolved toxicities from prior therapy\n* Significant cardiovascular disease\n* Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) \u2265 470 milliseconds (ms)\n* History of pneumonitis/interstitial lung disease\n* Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention",
        "NCTId": "NCT06400472"
    },
    {
        "ExclusionCriteria": "1. Multifocal disease within the breast.\n2. Has primary lesion \\> 3 cm in size radiographically or by physical examination. Pathologically proven nodal disease at diagnosis is not allowed.\n3. Has metastatic disease.\n4. Has a known additional malignancy that is progressing or requires active treatment in the last 5 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, DCIS of the breast, or in situ cervical cancer that has undergone potentially curative therapy.\n5. Patients for whom radiotherapy for breast cancer is contraindicated because of medical reasons (e.g., connective tissue disorder or prior ipsilateral breast radiation).\n6. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.\n7. Has a known history of active TB (Bacillus Tuberculosis).\n8. Has severe hypersensitivity (\u2265 Grade 3) to pembrolizumab or any of its excipients.\n9. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\n10. Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.\n11. Has an active infection requiring systemic therapy.\n12. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n13. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n14. Is pregnant or breastfeeding, or expected to conceive children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment.\n\n    The effects of MK-3745 on the developing human fetus are unknown. For this reason and because monoclonal antibody neoplastic agents are known to be teratogenic, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately.\n15. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137).\n16. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \\[qualitative\\] is detected).\n17. Has received a live vaccine within 30 days of planned start of study therapy.\n18. Has a medical history of allogenic stem cell transplant\n19. Has received a solid organ transplant\n20. Has a known history of Human Immunodeficiency Virus (HIV) infection. Note: No HIV testing is required unless mandated by local health authority.",
        "NCTId": "NCT02977468"
    },
    {
        "ExclusionCriteria": "* Patient not eligible for PD-1 inhibitor per the patient's medical oncologist\n* No disease amenable for cryoablation\n* Pembrolizumab therapy not planned as part of standard of care",
        "NCTId": "NCT06246968"
    },
    {
        "ExclusionCriteria": "* Have received anticancer therapy including chemotherapy, radiation therapy, immunotherapy, biologic, or any investigational therapy within 28 days or 5 half-lives of the drug (whichever is shorter) prior to the first dose of ABBV-400. Palliative radiation therapy for bone, skin, or subcutaneous metastases with 10 fractions or less is permitted and not subject to a washout period.\n* Unresolved AEs \\> Grade 1 from prior anticancer therapy except for alopecia.\n* History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, nor any evidence of active ILD or pneumonitis, including but not limited to those listed in the protocol.\n* History of clinically significant, intercurrent lung-specific illnesses, including those laid out in the protocol.\n* Untreated brain or meningeal metastases (i.e., participants with history of metastases are eligible provided they do not require ongoing steroid treatment for cerebral edema and have shown clinical and radiographic stability for at least 14 days after definitive therapy). Participants may continue on antiepileptic therapy if required.\n* History of other active malignancy, with the exception of those laid out in the protocol.\n* Any autoimmune, connective tissue or inflammatory disorders with documented or suspicious pulmonary involvement at screening (i.e., rheumatoid arthritis, Sjogren's, sarcoidosis etc.), and prior pneumonectomy.",
        "NCTId": "NCT06084481"
    },
    {
        "ExclusionCriteria": "* Patients who have had chemotherapy or radiotherapy within \u2265 2 weeks before entering the study or those who have not recovered from adverse events due to agents administered more than \u2265 4 weeks earlier.\n* Patients may not be receiving any other investigational agents.\n* The known history human immunodeficiency virus, acute and chronic Hepatitis B or C, or acute or previously treated tuberculosis.\n* Patients with untreated brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to leflunomide or teriflunomide.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\n* Patients must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.",
        "NCTId": "NCT03709446"
    },
    {
        "ExclusionCriteria": "* History of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke, significant brain trauma) at any time in the past. History of loss of consciousness or transient ischemic attack within 12 months.\n* History of brain metastases or leptomeningeal disease.\n* Prior antiandrogen therapy (AR antagonist or CYP17 inhibitors).\n* Other concurrent investigational anticancer agents.\n* Confirmed QT interval with Fridericia correction (QTcF) \\> 480 msec.\n* Any severe concurrent disease, infection, or comorbid condition that renders the patient inappropriate for enrollment in the opinion of the investigator or that interferes with the patient's ability to participate in the study requirements.\n* Pregnant patients are not eligible for study.\n* Women with a history of unexplained vaginal bleeding or with endometrial hyperplasia with atypia or endometrial carcinoma are excluded from study.\n* An active gastrointestinal disorder affecting absorption (e.g., gastrectomy, uncontrolled celiac disease).\n* Use of concurrent or chronic daily corticosteroid use. Topical or inhaled corticosteroids are permitted.\n* Use of concurrent medications that are strong inducers/inhibitors or substrates of CYP3A4. Patients may be switched to alternative medications for eligibility purposes. A list of CYP3A4 substrates, inducers, and/or inhibitors\n* Hypersensitivity reaction to the active pharmaceutical ingredient or any of the tablet components, including Labrasol, butylated hydroxyanisole, and butylated hydroxytoluene.",
        "NCTId": "NCT06099769"
    },
    {
        "ExclusionCriteria": "* Positive serum pregnancy test or women who are lactating.\n* Received prior therapy with an agent directed to another stimulatory or coinhibitory T-cell receptor.\n* Individuals may not have received systemic anticancer treatment (with the exception of endocrine therapy) within the previous 6 months or radiation therapy within 2 weeks prior to enrollment.\n* Individuals may not be participating in a study with an investigational agent or investigational device within 4 weeks prior to randomization. Individuals participating in observational studies are eligible.\n* Have previously received topoisomerase 1 inhibitors or antibody drug conjugates containing a topoisomerase inhibitor.\n* Have an active second malignancy.\n* Have active serious infection requiring antibiotics.\n* Individuals positive for HIV-1 or 2 with a history of Kaposi sarcoma and/or Multicentric Castleman Disease.\n* Have active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.\n* Has an active autoimmune disease that has required systemic treatment in the past 2 years.\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
        "NCTId": "NCT05382286"
    },
    {
        "ExclusionCriteria": "Cohort Legend: Cohort 1: On-Treatment Responder (Biopsy), Cohort 2: Pre and On-Treatment (Biopsy), Cohort 3: On-Treatment Responder (Surgery), Cohort 4: Post-Treatment Vitiligo, Cohort 5: Post-Treatment Responder (Frozen)\n\n1. Concurrent disease or condition that would make the patient inappropriate for study participation, or any serious medical or psychiatric disorder that would interfere with safety.\n2. Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.\n3. Research Biopsy Study Cohorts 1,2,4: History of serious or life-threatening allergic reaction to local anesthetics (i.e., lidocaine, xylocaine).\n4. Pregnant women are excluded because there may be an increased risk to both mother and fetus in the setting of moderate sedation, which is required for biopsies of certain anatomic sites (e.g., liver, lung, bone). Also, ionizing radiation from CT-guided biopsies may pose a risk to the unborn fetus.\n5. Research Biopsy Study Cohorts 1,2,4: Active cardiac disease, defined as:\n\ni. Uncontrolled or symptomatic angina within the past 3 months. ii. History of clinically significant arrhythmias (such as ventricular tachycardia, ventricular fibrillation, torsades de pointes). Atrial fibrillation with controlled ventricular response on treatment is not an exclusion.\n\niii. Myocardial infarction \\< 6 months from study entry. iv. Uncontrolled or symptomatic congestive heart failure. f. Any other condition, which in the opinion of the patient's treating oncologist or the physician performing the biopsy procedure, would make participation in this protocol unreasonably hazardous for the patient.",
        "NCTId": "NCT05230186"
    },
    {
        "ExclusionCriteria": "For All Cohorts:\n\n* Subject has preexisting sensory or motor neuropathy Grade \u2265 2.\n* Subject has active central nervous system (CNS) metastases. Subjects with treated CNS metastases are permitted on study if all the following are true:\n\n  * CNS metastases have been clinically stable for \u2265 6 weeks prior to screening\n  * If requiring steroid treatment for CNS metastases, the subject is on a stable dose \u2264 20 mg/day of prednisone or equivalent for \u2265 2 weeks\n  * Baseline imaging scans show no evidence of new or enlarged brain metastasis\n  * Subject does not have leptomeningeal disease\n* Subject has ongoing clinically significant toxicity (Grade 2 or higher with the exception of alopecia) associated with prior treatment (including systemic therapy, radiotherapy or surgery).\n* Subjects with ongoing \u2265 Grade 3 immunotherapy-related hypothyroidism or panhypopituitarism are excluded. Subjects with ongoing immunotherapy-related colitis, uveitis, myocarditis or pneumonitis, or subjects with other immunotherapy-related AEs requiring high doses of steroids (\\> 20 mg/day of prednisone or equivalent), are excluded. Subject with \u2264 Grade 2 immunotherapy-related hypothyroidism or panhypopituitarism may be enrolled when well maintained/controlled on a stable dose of hormone replacement therapy (if indicated).\n* Subject has a history of uncontrolled diabetes mellitus within 3 months before the first dose of study treatment. Uncontrolled diabetes (within 3 months before first dose) is defined as hemoglobin A1c (HbA1c) \u2265 8% or HbA1c between 7 and \\< 8% with associated diabetes symptoms (polyuria or polydipsia) that are not otherwise explained. The lowest HbA1c during the screening period will be used to determine eligibility.\n* Subject has prior treatment with enfortumab vedotin or other monomethyl auristatin E (MMAE) based antibody-drug conjugates (ADCs).\n* Subject has a second malignancy diagnosed within 3 years before first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Subjects with non-melanoma skin cancer, localized prostate cancer treated with curative intent with no evidence of progression, low-risk or very low-risk (per standard guidelines) localized prostate cancer under active surveillance/watchful waiting without intent to treat, or carcinoma in situ of any type (if complete resection was performed) are allowed.\n* Subject is currently receiving systemic antimicrobial treatment for viral, bacterial, or fungal infection at the time of first dose of study treatment. Routine antimicrobial prophylaxis is permitted.\n* Subject has known active hepatitis B (e.g., hepatitis B surface antigen \\[HBsAg\\] reactive) or active hepatitis C (e.g., hepatitis C virus \\[HCV\\] RNA \\[qualitative\\] is detected).\n* Subject has known history of human immunodeficiency virus (HIV) infection (HIV 1 or 2).\n* Subject has documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction or cardiac symptoms (including congestive heart failure) consistent with New York Heart Association Class III-IV within 6 months prior to the first dose of study drug.\n* Subject has major surgery within 4 weeks prior to first dose of study drug.\n* Subject had radiotherapy, chemotherapy, biologics, investigational agents, and/or antitumor treatment with immunotherapy that is not completed 2 weeks prior to first dose of study drug.\n* Subject has known hypersensitivity to enfortumab vedotin or to any excipient contained in the drug formulation of enfortumab vedotin (including histidine, trehalose dihydrate and polysorbate 20) OR subject has known hypersensitivity to biopharmaceutical produced in Chinese hamster ovary cells.\n* Subject has known active keratitis or corneal ulcerations. Subject with superficial punctate keratitis is allowed if the disorder is being adequately treated.\n* Subject has any condition which makes the subject unsuitable for study participation.\n\nCohort 9: 1L HNSCC\n\n* Had PD within 6 months of completion of curatively intended systemic treatment for locoregionally advanced HNSCC.\n* Has had an allogeneic tissue/solid organ transplant. Has severe hypersensitivity (\u2265grade 3) to pembrolizumab and/or any of its excipients.\n* Has a history of (non-infectious) pneumonitis / interstitial lung disease that required steroids or has current pneumonitis / interstitial lung disease.\n* Has a history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.\n* Has a life expectancy of less than 3 months and/or has rapidly progressing disease (e.g. tumor bleeding, uncontrolled tumor pain) in the opinion of the treating investigator.\n* Active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs).\n\n  1. Replacement therapy (e.g., thyroxine, insulin, physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.\n  2. Brief (\\<7 days) use of systemic corticosteroids is allowed when use is considered standard of care.\n  3. Subjects with vitiligo, psoriasis, type 1 diabetes mellitus, hypothyroidism, or resolved childhood asthma/atopy will not be excluded.\n  4. Subjects requiring intermittent use of bronchodilators, inhaled steroids, or local steroid injections will not be excluded.\n  5. Subjects with hypothyroidism that is stable with hormone replacement or Sj\u00f6gren's syndrome will not be excluded.\n* Has an active infection requiring systemic therapy.\n* Has received prior therapy with an anti-PD-1 or anti-PD-L1 agent in the recurrent/metastatic setting. If anti-PD-1 or anti-PD-L1 agent was given as part of curative intent therapy, it must be at least 1 year since last dose.\n* Has received a live vaccine within 30 days of planned start of study therapy. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette Gu\u00e9rin, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist\u00ae) are live attenuated vaccines and are not allowed.\n* Subject has active tuberculosis",
        "NCTId": "NCT04225117"
    },
    {
        "ExclusionCriteria": "* Receipt of \\> 3 lines of systemic therapy in mTNBC patients\n* A WOCBP who has a positive urine pregnancy test within 72 hours or a serum pregnancy test within 14 days prior to treatment (see Appendix C). If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n\n  * A minimum 2-week washout required for all anti-cancer agents, including cytotoxic chemotherapeutic agents, immunotherapy, biologic therapy, and targeted therapies. A 3-4 week washout is preferred when reasonable.\n  * Note: in the event that 72 hours have elapsed between the screening pregnancy test and the first dose of study treatment, another pregnancy test (urine or serum) must be performed and must be negative in order for subject to start receiving study medication.\n* Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks (preferred) or a minimum of 2 weeks prior to the start of study treatment.\n\n  * Note: Participants must have recovered from all AEs due to previous therapies to \u2264 Grade 1 or baseline. Participants with \u2264 Grade 2 neuropathy may be eligible.\n  * Note: If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment.\n* Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (\u2264 2 weeks of radiotherapy) to non-CNS disease.\n* Has previously experienced grade 3 or higher immune-mediated adverse events from prior courses of immunotherapy.\n* Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Gu\u00e9rin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist\u00ae) are live attenuated vaccines and are not allowed.\n\n  \u00b0 Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist\u00ae) are live attenuated vaccines, and are not allowed.\n* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 (preferred, or 2 weeks minimum) weeks prior to the first dose of study treatment.\n\n  * Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been at least 2 weeks (prefer 4 weeks) after the last dose of the previous investigational agent.\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.\n* Has a known additional malignancy that is progressing or has required active treatment within the past 2 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.\n* Has severe hypersensitivity (\u2265 Grade 3) to pembrolizumab and/or olaparib and/or any of their excipients.\n* Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\n* Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.\n* Has an active infection requiring systemic therapy.\n* Has a known history of Human Immunodeficiency Virus (HIV).\n\n  * Note: No HIV testing is required.\n* Has a known history of Hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] reactive) or known active Hepatitis C virus (defined as HCV RNA is detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority.\n* Has a known history of active TB (Bacillus Tuberculosis).\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n* Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment\n* Has had an allogenic tissue/solid organ transplant\n* Resting ECG indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (eg., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, QTcF prolongation \\> 500 ms, electrolyte disturbances, etc.), or patients with congenital long QT syndrome.\n* Persistent toxicities (\\>Common Terminology Criteria for Adverse Event (CTCAE 5.0) grade 2) caused by previous cancer therapy, excluding alopecia.\n* Patients with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of MDS/AML.\n* Patients with symptomatic uncontrolled brain metastases. A scan to confirm the absence of brain metastases is not required. The patient can receive a stable dose of corticosteroids before and during the study as long as these were started at least 4 weeks prior to treatment. Patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days.\n* Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on High Resolution Computed Tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consent.\n* Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.\n* Concomitant use of known strong CYP3A inhibitors (eg. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (eg. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting olaparib is 2 weeks.\n* Concomitant use of known strong (eg. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort ) or moderate CYP3A inducers (eg. bosentan, efavirenz, modafinil). The required washout period prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.\n* Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.\n* Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT).\n* Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.\n* Previous enrollment in the present study.",
        "NCTId": "NCT04683679"
    },
    {
        "ExclusionCriteria": "* History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 3 years before randomization and of low potential risk for recurrence.\n* Evidence of distant disease.\n* Clinically significant corneal disease.\n* Has active or uncontrolled hepatitis B or C virus infection.\n* Known HIV infection that is not well controlled.\n* Uncontrolled infection requiring i.v. antibiotics, antivirals or antifungals; suspected infections; or inability to rule out infections.\n* Known to have active tuberculosis infection\n* Resting ECG with clinically significant abnormal findings.\n* Uncontrolled or significant cardiac disease.\n* History of non-infectious ILD/pneumonitis\n* Any prior or concurrent surgery, radiotherapy or systemic anticancer therapy for TNBC or hormone receptor-low/HER2-negative breast cancer\n* For females only: is pregnant (confirmed with positive serum pregnancy test) or breastfeeding, or planning to become pregnant.\n* Female participants should refrain from breastfeeding from enrolment throughout the study and for at least 7 months after last dose of study intervention, or as dictated by local PI for SoC if longer.",
        "NCTId": "NCT06112379"
    },
    {
        "ExclusionCriteria": "* Individual with known or suspected uncontrolled CNS metastases\n* Individual with uncontrolled hypercalcemia\n* Individual with uncontrolled diabetes\n* Individual with evidence of corneal keratopathy or history of corneal transplant\n* Any serious unresolved toxicities from prior therapy\n* Significant cardiovascular disease\n* Current of history of intestinal obstruction in the previous 3 months\n* Recent thromboembolic event or bleeding disorder\n* Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) \u2265 470 ms\n* History of pneumonitis/interstitial lung disease\n* History of Grade \u22653 skin toxicity when receiving enfortumab vedotin\n* Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention",
        "NCTId": "NCT06238479"
    },
    {
        "ExclusionCriteria": "* As judged by investigator, severe or uncontrolled medical conditions including systemic diseases, history of allogeneic organ transplant and active bleeding diseases, ongoing or active infection, significant cardiac or psychological conditions.\n* History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 3 years before Cycle 1 Day 1 and of low potential risk for recurrence.\n* Neoplastic spinal cord compression or active brain metastases, leptomeningeal carcinomatosis or history of leptomeningeal carcinomatosis.\n\n  - Participants with treated clinically inactive brain metastases that are no longer symptomatic, who require no treatment with corticosteroids or anticonvulsants, may be included in the study if they have recovered from acute toxic effects of radiotherapy.\n* Uncontrolled infection requiring IV antibiotics, antivirals or antifungals.\n* Active or uncontrolled hepatitis B or C virus infection.\n* Known HIV infection that is not well controlled.\n* Uncontrolled or significant cardiac disease.\n* History of non-infectious ILD/pneumonitis (including radiation pneumonitis) that required steroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.\n* Severe pulmonary function compromise.\n* Clinically significant corneal disease.\n* Active or prior documented autoimmune or inflammatory disorders.\n* Prior exposure to any treatment including ADC containing a chemotherapeutic agent targeting topoisomerase I and TROP2-targeted therapy.\n* Any concurrent anti-cancer treatment.\n* Participants with a known severe hypersensitivity to PD-1/PD-L1 inhibitors or Dato-DXd.\n* Currently pregnant (confirmed with positive pregnancy test), breastfeeding or planning to become pregnant.",
        "NCTId": "NCT06103864"
    },
    {
        "ExclusionCriteria": "Dose Escalation and Dose Expansion Cohorts Patients meeting any of the following criteria are ineligible for participation in the study.\n\n1. Women who are pregnant or lactating. Women of child-bearing potential (WOCBP) not using adequate birth control see Appendix H: Forms of contraception.\n2. Patients with known central nervous system (CNS) or leptomeningeal metastases not controlled by prior surgery, radiotherapy or requiring corticosteroids to control symptoms, or patients with symptoms suggesting CNS involvement for which treatment is required.\n3. Patients with primary brain tumors.\n4. Patients with any hematologic malignancy. This includes leukemia (any form), lymphoma, and multiple myeloma.\n5. Patients with any of the following hematologic abnormalities at baseline. (Patients may have received a red blood cell product transfusion prior to study, if clinically warranted.):\n\n   * Absolute neutrophil count (ANC) \\< 1,500 per mm3\n   * Platelet count \\< 100,000 per mm3\n   * Hemoglobin \\< 8.0 gm/dL\n6. Patients with any of the following serum chemistry abnormalities at baseline:\n\n   * Total bilirubin \u2265 1.5 \u00d7 the ULN for the institution value\n   * AST or ALT \u2265 3 \u00d7 the ULN for the institution value (\u2265 5 \u00d7 if due to hepatic involvement by tumor)\n   * Creatinine \u2265 1.5 \u00d7 ULN for the institution value (or a calculated creatinine clearance \\< 60 mL/min/1.73 m2\\* )\n7. Patients with a significant active cardiovascular disease or condition, including:\n\n   * Congestive heart failure (CHF)requiring therapy\n   * Need for antiarrhythmic medical therapy for a ventricular arrhythmia\n   * Severe conduction disturbance\n   * Unstable angina pectoris requiring therapy\n   * QTc interval \\> 450 msec (males) or \\> 470 msec (females)\n   * QTc interval \u2264 300 msec\n   * History of congenital long QT syndrome or congenital short QT syndrome\n   * LVEF \\< 50% as measured by echocardiography or MUGA scan\n   * Uncontrolled hypertension (per the Investigator's discretion)\n   * Class III or IV cardiovascular disease according to the New York Heart Association's (NYHA) Functional Criteria (see APPENDIX C: New York Heart Association's Functional Criteria).\n   * Myocardial infarction (MI) within 6 months prior to first study drug administration\n8. Patients with a known or suspected hypersensitivity to any of the components of OTS167.\n9. Patients with a known history of human immunodeficiency virus (HIV) or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).\n10. Patients with any other serious/active/uncontrolled infection, any infection requiring parenteral antibiotics, or unexplained fever \\> 38\u00baC within 1 week prior to first study drug administration.\n11. Patients with inadequate recovery from any prior surgical procedure, or patients having undergone any major surgical procedure within 4 weeks prior to first study drug administration.\n12. Patients with any other life-threatening illness, significant organ system dysfunction, or clinically significant laboratory abnormality, which, in the opinion of the Investigator, would either compromise the patient's safety or interfere with evaluation of the safety of the study drug.\n13. Patients with a psychiatric disorder or altered mental status that would preclude understanding of the informed consent process and/or completion of the necessary studies.\n14. Patients with the inability or with foreseeable incapacity, in the opinion of the Investigator, to comply with the protocol requirements.\n15. Any anti-neoplastic agent or monoclonal antibody therapy for the primary malignancy (standard or experimental) within 2 weeks prior to first study drug administration.\n16. Radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a limited field of radiation for palliation within 1 week of the first dose of study treatment. If acute symptoms of radiation have fully resolved, the extent and timing of radiotherapy for eligibility can be discussed between Investigator and Sponsor.\n17. Patients requiring surgery for the primary or metastatic primary malignancy.\n18. Herbal preparations or related over the counter (OTC) preparations/supplements containing herbal ingredients within 1 week prior to first study drug administration and during study.\n19. Systemic hormonal therapy which is not related to breast cancer treatment (standard or experimental) within 1 week prior to first study drug administration and during study. The following therapies are allowed:\n\n    * Hormonal therapy (e.g., Megace) for appetite stimulation\n    * Nasal, ophthalmic, inhaled, and topical glucocorticoid preparations\n    * Oral replacement glucocorticoid therapy for adrenal insufficiency\n    * Low-dose maintenance steroid therapy for other conditions (excluding steroid tapers for brain edema/metastases/radiation)\n    * Hormonal contraceptive therapy (for WOCBP must be combined with non-hormonal contraceptive equivalent to a double-barrier method)\n20. Any other investigational treatments during study. This includes participation in any medical device or therapeutic intervention clinical trials.\n\n    Dose expansion Cohort - TNBC\n21. Patients with only lesions that cannot be accessed for biopsy.",
        "NCTId": "NCT02926690"
    },
    {
        "ExclusionCriteria": "* Patients who are not considered to be candidates for carboplatin + gemcitabine for first line therapy of their metastatic triple negative breast cancer are not eligible.\n* Patients who have had chemotherapy, radiotherapy (to more than 30% of the bone marrow), or biologic therapy within 30 days (42 days for nitrosoureas or mitomycin C) prior to entering the study.\n* Patients who have received prior immunotherapy for metastatic disease.\n* Patients who have not recovered from grade \\>= 2 adverse events due to prior anti-cancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria.\n\n  * Patients with grade \\>= 2 neuropathy will be evaluated on a case-by-case basis after consultation with the study physician.\n* Patients who are receiving any other investigational agents or who have received an investigational agent within the last 30 days.\n* Receipt of live attenuated vaccination within 6 months prior to study entry or within 30 days of receiving durvalumab (MEDI4736) and tremelimumab.\n\n  * Note: Patients, if enrolled, should not receive live vaccine whilst receiving study treatment and up to 30 days after the last dose of study treatment.\n* Major surgical procedure within 28 days prior to the first dose of durvalumab (MEDI4736) and tremelimumab. Local surgery of isolated lesions for palliative intent is acceptable.\n* Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab (MEDI4736) or tremelimumab. The following are exceptions to this criterion:\n\n  * Intranasal, inhaled, topical steroids or local steroid injections (e.g. intra-articular injection)\n  * Systemic corticosteroids at physiological doses which are not to exceed 10 mg/day of prednisone or an equivalent corticosteroid\n  * Steroids as premedication for hypersensitivity reactions (e.g. CT scan premedication).\n* Known central nervous system (CNS) disease, except for treated asymptomatic CNS metastases. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to durvalumab (MEDI4736) and tremelimumab. Known allergy, or history of serious adverse reaction to vaccines, such as anaphylaxis, hives or respiratory difficulty.\n* Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) \\>= 470 ms calculated from 3 electrocardiograms (ECGs) (within 15 minutes at 5 minutes apart).\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, evidence of any acute or chronic viral illness or disease, or psychiatric illness/social situations that would limit compliance with study requirements.\n* Pregnant women are excluded from this study because durvalumab (MEDI4736) and tremelimumab has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with durvalumab (MEDI4736) and tremelimumab, breastfeeding should be discontinued if the mother is treated with durvalumab (MEDI4736) and tremelimumab. These potential risks may also apply to other agents used in this study. A negative serum pregnancy test is required no more than 7 days before study entry.\n* Active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\n* History of pneumonitis or interstitial lung disease.\n* History of active primary immunodeficiency.\n* Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination, and radiographic findings, and tuberculosis \\[TB\\] testing in line with local practice), hepatitis B (known positive hepatitis B virus \\[HBV\\] surface antigen \\[HBsAg\\] result), or hepatitis C. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[anti-HBc\\] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA).\n* The patient with a previous history of non-breast malignancy is eligible for this study only if the patient meets the following criteria for a cancer survivor. A cancer survivor is eligible provided the following criteria are met:\n\n  * Patient has undergone potentially curative therapy for all prior malignancies.\n  * Patients have been considered disease free for at least 1 year (with the exception of basal cell or squamous cell carcinoma of the skin or carcinoma-in-situ of the cervix).\n* Patients with a strong likelihood of non-adherence (such as difficulties in adhering to follow-up schedule due to geographic distance from the treatment facility) should not be knowingly registered.\n* History of allogeneic organ transplantation.",
        "NCTId": "NCT03606967"
    },
    {
        "ExclusionCriteria": "* Subjects currently receiving other anticancer therapies\n* Any prior treatment with an investigational agent targeting CD28\n* History of a life-threatening adverse event related to prior immunotherapy\n* Known active central nervous system involvement by malignant disease. Subjects with previously treated brain metastases may participate provided they are radiologically and clinically stable",
        "NCTId": "NCT05585034"
    },
    {
        "ExclusionCriteria": "* Have any unresolved toxicity of Grade \u2265 2 from previous anti-cancer treatment, except for alopecia, chronic neuropathy \\> 6 months, or changes in skin pigmentation\n* Have known or suspected brain metastases, unless they are clinically stable\n* Known autoimmune disease requiring immunosuppressive treatment requiring the equivalent of more than 10 mg prednisone daily\n* History of grade 3 immune-related pneumonitis or colitis",
        "NCTId": "NCT05958199"
    },
    {
        "ExclusionCriteria": "* Positive serum pregnancy test or women who are lactating\n* Received systemic anticancer treatment within the previous 6 months or radiation therapy within 2 weeks prior to enrollment\n* Have not recovered from adverse events (AEs) due to a previously administered agent at the time study entry\n* May not be participating in a study with an investigational agent or investigational device within 4 weeks prior to randomization. Individuals participating in observational studies are eligible\n* Previously received topoisomerase 1 inhibitors or antibody drug conjugates containing a topoisomerase inhibitor\n* Active second malignancy\n* Active serious infection requiring antibiotics\n* Positive for HIV-1 or 2 with a history of Kaposi sarcoma and/or Multicentric Castleman Disease\n* Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
        "NCTId": "NCT05382299"
    },
    {
        "ExclusionCriteria": "1. Stage IV (metastatic) TNBC.\n2. History of prior invasive breast cancer, or evidence of recurrent disease following preoperative therapy and surgery.\n3. Severe or uncontrolled medical conditions including systemic diseases, history of allogeneic organ transplant and active bleeding diseases, ongoing or active infection, serious chronic gastrointestinal conditions associated with diarrhea chronic diverticulitis or previous complicated diverticulitis.\n4. History of another primary malignancy except for adequately resected basal cell carcinoma of the skin or squamous cell carcinoma of the skin, in situ disease (including ductal carcinoma in situ) that has undergone potentially curative therapy, or other solid malignancy treated with curative intent with no known active disease within 5 years before randomisation and of low potential risk for recurrence.\n5. Persistent toxicities caused by previous anticancer therapy, excluding alopecia, not yet improved to Grade \u2264 1 or baseline. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention may be included (eg, hearing loss).\n6. Active or prior documented autoimmune or inflammatory disorders.\n7. Clinically significant corneal disease.\n8. Active or uncontrolled hepatitis B or C virus infection.\n9. Known HIV infection that is not well controlled\n10. Active tuberculosis infection.\n11. Mean resting corrected QTcF \\> 470 ms regardless of gender, obtained from triplicate 12-lead ECGs performed at screening.\n12. Uncontrolled or significant cardiac disease.\n13. History of non-infectious ILD/pneumonitis including radiation, pneumonitis that required steroids, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.\n14. Has severe pulmonary function compromise.\n15. Any known active liver disease.\n16. Grade \u2265 2 peripheral neuropathy of any aetiology.\n17. Prior exposure to a PD-1/PD-L1 inhibitor other than pembrolizumab.\n18. Current or prior use of immunosuppressive medication within 14 days prior to randomisation.\n19. Participants with a known severe hypersensitivity to Dato-DXd or any of the excipients of these products including but not limited to polysorbate 80 or other monoclonal antibodies.\n20. Participants with a known severe hypersensitivity to PD-1/PD-L1 inhibitors.\n21. Participation in another clinical study with a study intervention or investigational medicinal device administered in the last 4 weeks prior to randomisation, randomisation into a prior Dato-DXd, T-DXd, or durvalumab study regardless of treatment assignment.\n22. Currently pregnant (confirmed with positive pregnancy test), breastfeeding or planning to become pregnant.",
        "NCTId": "NCT05629585"
    },
    {
        "ExclusionCriteria": "* Serious medical co-morbidities precluding radiotherapy, determined at the discretion of the treating investigator.\n* Pregnant or lactating women.\n* Other active malignancy within the last year, even if without evidence of disease.\n* Clinical or radiological evidence of spinal cord compression\n* Malignant pleural effusion or ascites.\n* Patients whose entry to the trial will cause unacceptable clinical delays in their planned management.",
        "NCTId": "NCT03808337"
    },
    {
        "ExclusionCriteria": "(exclusion criteria not marked) Key Inclusion Criteria For All Phases and Cohorts:\n\n1. Recovered from toxicity to prior anticancer therapy\n2. Adequate bone marrow and organ function\n3. No known active or symptomatic central nervous system (CNS) disease\n\nCohort-Specific Inclusion Criteria: In addition to the inclusion criteria listed above, the following criteria apply for enrollment into specific cohorts.\n\nPhase 1 (NUV-868 Monotherapy)\n\n1. Patients with advanced solid tumors that have progressed during or after treatment with approved therapies or for which there is no standard effective therapy available\n2. Life expectancy of \\> 3 months\n3. Eastern Cooperative Oncology Group Performance Status \u2264 2\n4. Measurable or non-measurable disease\n\nPhase 1b (NUV-868 in Combination With Enzalutamide or Olaparib)\n\n1. Life expectancy of \\> 3 months\n2. Eastern Cooperative Oncology Group Performance Status \u2264 2\n3. (Select cohorts only) Measurable disease\n4. Patient must be able to read and write sufficiently to document food intake and study drug dosing on the Dosing Diary or must have a caregiver who is willing and able to complete the Dosing Diary with the patient.\n5. One of the following tumor types:\n\n   1. Ovarian: Platinum-resistant OR platinum-refractory high grade serous ovarian, fallopian, or primary peritoneal cancer in the relapsed setting\n   2. Pancreatic: Pancreatic ductal adenocarcinoma (PDAC) with progression on or after treatment with at least one line of systemic chemotherapy in the advanced setting\n   3. Prostate: Histologically confirmed, metastatic adenocarcinoma of the prostate (adenocarcinoma/high grade carcinoma with neuroendocrine features is allowed) with progression on or after treatment with at least one NHT in the metastatic setting\n   4. Breast: Triple-negative breast cancer (TNBC) with progression on or after treatment with at least one line of systemic chemotherapy in the advanced setting\n   5. Other advanced tumors (only Phase 1b dose escalation, NUV-868 + olaparib): the study Medical Monitor must approve enrollment.\n   6. For all tumor types: Patients will be allowed in the study regardless of their BRCA/HRR status.\n\nPhase 2\n\n1. Life expectancy of \\> 6 months\n2. (Select cohorts only): At least one measurable lesion defined by standard criteria\n3. Eastern Cooperative Oncology Group Performance Status \u2264 1\n4. One of the following tumor types:\n\n   1. Ovarian: Platinum-resistant or platinum- refractory high grade serous ovarian, fallopian, or primary peritoneal cancer in the relapsed setting\n   2. Pancreatic: Progression on or after treatment with at least one line of systemic chemotherapy in the advanced setting\n   3. Prostate: Histologically confirmed, metastatic adenocarcinoma of the prostate (adenocarcinoma/high grade carcinoma with neuroendocrine features is allowed) with progression on or after treatment with at least one NHT in the metastatic setting\n   4. Breast: TNBC with progression on or after treatment with at least one line of systemic chemotherapy in the advanced setting\n\nKey Exclusion Criteria For All Phases and Cohorts:\n\n1. Have received chemotherapy, hormonal therapy (except for ongoing luteinizing hormone-releasing hormone \\[LHRH\\] analogs in male patients and premenopausal women), radiation, or biological anticancer therapy within 14 days prior to the first dose of NUV-868.\n2. Received treatment with an investigational agent for any indication within 14 days for non-myelosuppressive agent, or within 21 days or \\< 5 half-lives (whichever is longer) for myelosuppressive agent, prior to the first dose of study treatment.\n3. Requires medications that are known to be strong (or moderate for olaparib) inducers and/or strong (or moderate for olaparib) inhibitors of CYP3A4/5 enzymes.\n4. Female patients who are pregnant of breastfeeding.",
        "NCTId": "NCT05252390"
    },
    {
        "ExclusionCriteria": "* Use of any other investigational agents within 30 days of starting study treatment\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study agent or accompanying supportive medications.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements",
        "NCTId": "NCT01042379"
    },
    {
        "ExclusionCriteria": "* Receiving other treatments specifically administered to treat LMD within the last 2 weeks or 5 half-lives of the agent, whichever is less. However, all other treatments to control systemic disease or bulk CNS disease will be eligible, provided the therapy is not a phase I agent, an agent which significantly and unequivocally penetrates the CSF (e.g., high-dose methotrexate, thiotepa, high-dose ara-C) per PI discretion.\n* The use of any immunotherapy within the last four weeks.\n* Patients with a ventriculoperitoneal or ventriculoatrial shunt must have an on/off device in their shunt systems to be eligible for the study. Patients must be able to tolerate shunt closure for \\~4 hours without development of clinical signs of increased intracranial pressure. Patients unable to tolerate shunt closure for \\~4 hours will not be eligible for the study.\n* Unable or unwilling to have a contrast-enhanced brain MRI.\n* Known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin,squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.\n* Has an active infection requiring systemic therapy which in the opinion of the investigator will increase the risk to the patient.\n* Had major surgical procedure, or significant traumatic injury within two weeks. Ommaya placement is allowed.\n* Has a history of current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n* Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 90 days after the last dose of trial treatment.\n* Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1, 2 antibodies). Testing is not mandatory.\n* Has known active or chronic hepatitis B (HBV) or hepatitis C virus (HCV). Testing is not mandatory.\n* ORGAN TRANSPLANTATION: Prior organ transplantation including allogenic stem-cell transplantation.\n* Other severe acute or chronic medical conditions or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.\n* Has received a blood transfusion in the two weeks prior to leukapheresis.\n* Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Gu\u00e9rin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist\u00ae) are live attenuated vaccines and are not allowed. Current COVID vaccines are not live vaccines.",
        "NCTId": "NCT05809752"
    },
    {
        "ExclusionCriteria": "(exclusion criteria not marked) General Inclusion:\n\n* Written informed consent, according to local guidelines, signed and dated by the patient or by a legal guardian prior to the performance of any study-specific procedures, sampling or analyses\n* At least 18 years-of-age at the time of signature of the informed consent form\n* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1\n* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\n* Acceptable renal, hepatic, hematologic and coagulation functions\n* Negative pregnancy test for women of childbearing potential\n* Male participants with female partners of childbearing potential and female participants of childbearing potential are required to follow highly effective contraception\n* All patients must have tumor tissue (fresh or archived) available for analysis of EphA2 tumor expression and other biomarkers. In the absence of available tumor tissue, patients must be willing to undergo a biopsy to provide fresh tumor samples\n* Life expectancy \u226512 weeks after the start of BT5528 treatment according to the Investigator's judgment.\n* Must be willing and able to comply with the protocol and study procedures.\n\nAdditional inclusion criteria for Phase I (dose escalation phase, with BT5528 alone or in combination with nivolumab):\n\n* Metastatic recurrent histologically confirmed malignant solid tumors historically known for high EphA2 tumor expression. Confirmation of EphA2 expression prior to enrollment is not required for participants with ovarian cancer and specific other individual tumor types.\n* Exhausted all appropriate treatment options per local guidelines\n\nAdditional inclusion criteria for Phase II (dose expansion phase, with BT5528 alone):\n\n* Participants with metastatic recurrent disease histologically confirmed to be non-small cell lung cancer, ovarian cancer, triple-negative breast cancer (TNBC), gastric/upper gastrointestinal (GI) cancer, head and neck (H\\&N) cancer, urothelial cancer are eligible and must have failed or are ineligible for all appropriate treatment options per local guidelines and must have evidence of radiographic progression on the most recent line of therapy\n* Patients with urothelial cancer who have previously received treatment with enfortumab vedotin (EV) are eligible to the study. Patients who received EV and showed disease progression within 6 months of treatment start are planned for less than 50% of total patients enrolled in the cohort\n\nExclusion criteria (all participants):\n\n* Chemotherapy treatments within 14 days prior to first dose of study treatment, other anticancer treatments, treatment within 28 days or 5 half-lives, whichever is the shorter\n* Experimental treatments within 4 weeks of first dose of BT5528\n* Prior toxicities must have resolved to Grade 1 per Common Terminology Criteria for Adverse Events (CTCAE) v 5.0 (except alopecia which can be Grade 2)\n* Current treatment with strong inhibitors or inducers of CYP3A4 or strong inhibitors of P-gp\n* Known sensitivity to any of the ingredients of the investigational product or monomethyl auristatin E (MMAE)\n* Any condition, therapy or laboratory abnormality that might confound the results of the study, interfere with the patient's participation, or is not in the best interest of the patient to participate in the opinion of the investigator including but not limited to specific cardiovascular criteria\n* Major surgery (excluding placement of vascular access) within 4 weeks of first dose of BT5528 study treatment and must have recovered adequately prior to starting study therapy\n* Receipt of live vaccine within 30 days of study treatment\n* Untreated CNS metastases or leptomeningeal disease\n* Uncontrolled hypertension (systolic BP \u2265160 mmHg or diastolic BP \u2265100 mmHg that is not responsive to intervention) at screening or prior to initiation of study drug.\n* History or current evidence of any condition, therapy or laboratory abnormality that might confound the results of the study, interfere with the patient's participation, or is not in the best interest of the patient to participate in the opinion of the Investigator including but not limited to:\n\n  (a) Patients with history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction, congestive heart failure or symptoms of New York Heart Association Class III-IV documented within 6 months prior to first dose of BT5528 or: (i) Mean resting corrected QT interval (QTcF) \\>470 msec (ii) Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years-of-age, or any concomitant medication known to prolong the QT interval (iii) Any clinically important abnormalities (as assessed by the Investigator) in rhythm, conduction, or morphology of resting electrocardiograms (ECGs), e.g., complete left bundle branch block, third degree heart block\n* Known human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS). Note: Well controlled HIV will be allowed if the patient meets all the following criteria at inclusion:\n\n  1. CD4+ T-cell (CD4+) counts \u2265350 cells/uL;\n  2. HIV viral load \\<400 copies/mL\n  3. Without a history of opportunistic infection within the last 12 months.\n  4. On established antiretroviral therapy (ART) for at least 4 weeks. Use of anti-retroviral therapy is permitted, but should be discussed with the Medical Monitor on a case-by-case basis.\n* Patients with a positive hepatitis B surface antigen and/or anti-hepatitis B core antibody. Patients with a negative polymerase chain reaction (PCR) assay are permitted with appropriate antiviral therapy\n* Active hepatitis C infection with positive viral load if hepatitis C virus (HCV) antibody positive (if antibody is negative then viral load not applicable). Patients who have been treated for hepatitis C infection can be included if they have documented sustained virologic response of \u226512 weeks.\n* Thromboembolic events and/or bleeding disorders 3 months (e.g., deep vein thrombosis \\[DVT\\] or pulmonary embolism \\[PE\\]) prior to first dose\n* Prior history of pneumonitis with presence of residual symptoms\n* History of another malignancy within 3 years before the first dose of BT5528, or any evidence of residual disease from a previously diagnosed malignancy (excluding adequately treated with curative intent basal cell carcinoma, squamous cell of the skin, cervical intraepithelial neoplasia/cervical carcinoma in situ or melanoma in situ or ductal carcinoma in situ of the breast).\n* Systemic anti-infective treatment or fever within the last 14 days prior to first dose of BT5528 study treatment\n* Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol and/or follow-up procedures outlined in the protocol.\n\nAdditional Exclusion Criteria (BT5528 in combination with nivolumab):\n\n* Prior intolerance to immune checkpoint inhibitor\n* Known hypersensitivity to checkpoint inhibitor therapy\n* Prior organ transplant (including allogeneic)\n* Diagnosis of clinically relevant immunodeficiency\n* Active systemic infection requiring therapy\n* More than 10 mg daily prednisone equivalent or other strong immunosuppressant\n* History of autoimmune disease except alopecia or vitiligo\n* History of interstitial lung disease",
        "NCTId": "NCT04180371"
    },
    {
        "ExclusionCriteria": "* MSI-H, dMMR, POLE gene hotspot mutated, or known hypermutator phenotype\n* Previously received KIF18A inhibitor\n* Current CNS metastases or leptomeningeal disease\n* Cardiac parameters: MI or stroke \u2264 1 year, unstable angina/PE/DVT/CABG \u2264 6 months, NYHA Class \u2265 II, LVEF \\< 50%\n* Inability to comply with concomitant medication restrictions with respect to strong inhibitors and inducers of CYP3A, and clinical inhibitors of MDR1 (P-gp) and BCRP\n* Any clinically significant ascites or pleural effusions at time of enrollment, or any therapeutic paracentesis or thoracentesis within 28 days of planned first dose of study drug\n* Bowel obstruction or GI perforation within 6 months of planned first dose of study drug",
        "NCTId": "NCT05902988"
    },
    {
        "ExclusionCriteria": "* No stage IV (metastatic) breast cancer\n* No history of any prior (ipsi- or contralateral) invasive breast cancer. Prior DCIS is allowed\n* No evidence of recurrent disease following preoperative therapy and surgery\n* No known active liver disease, e.g. due to hepatitis B virus (HBV), hepatitis C virus (HCV), autoimmune hepatic disorders, or sclerosing cholangitis\n* No history of intolerance, including Grade 3 or 4 infusion reaction or hypersensitivity to pembrolizumab or murine proteins or any components of the product\n\n  \\* Note: Prior immune-related adverse events (irAEs) are allowed if they resolved and the patient tolerated subsequent therapy without requiring chronic steroids for the irAE\n* No medical conditions that require chronic systemic steroids (\\>10 mg prednisone daily or equivalent) or any other form of immunosuppressive medications and has required such therapy in the last two years. Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic therapy\n* Patients who are unable or unwilling to comply with the requirements of the protocol per investigator assessment are not eligible",
        "NCTId": "NCT05812807"
    },
    {
        "ExclusionCriteria": "* Women who are pregnant or breastfeeding\n* Primary central nervous system (CNS) malignancy\n* Untreated CNS metastases\n* Leptomeningeal metastases\n* Concurrent malignancy requiring treatment or history of prior malignancy active within 2 years prior to the first dose of study treatment\n* Active, known, or suspected autoimmune disease\n* Condition requiring systemic treatment with either corticosteroids within 14 days or other immunosuppressive medications within 30 days of the first dose of study treatment\n* Prior organ or tissue allograft\n* Uncontrolled or significant cardiovascular disease\n* Major surgery within 4 weeks of study drug administration\n* History of or with active interstitial lung disease or pulmonary fibrosis\n\nOther protocol-defined inclusion/exclusion criteria apply",
        "NCTId": "NCT04895709"
    },
    {
        "ExclusionCriteria": "* Has a history of malignancy, other than a tumor type specified in the Inclusion Criteria, except (a) adequately resected non-melanoma skin cancer, (b) curatively treated in situ disease, or (c) other solid tumors curatively treated, with no evidence of disease for \u22653 years.\n* Uncontrolled or significant cardiac disease including myocardial infarction or uncontrolled/unstable angina within 6 months prior to Cycle 1 Day 1.\n* History of congestive heart failure (New York Heart Association classes II-IV) or uncontrolled or significant cardiac arrhythmia, uncontrolled hypertension(resting systolic blood pressure \\>180 mm Hg or diastolic blood pressure \\>110 mm Hg).\n* Has a mean corrected QT interval (QTcF) prolongation to \\>470 ms based on of the screening triplicate 12-lead ECGs.\n* Has a history of non-infectious interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.\n* Has clinically significant corneal disease.\n* Has an uncontrolled infection requiring IV antibiotics, antivirals, or antifungals. Has active human immunodeficiency virus (HIV) infection that is not well controlled. All of the following criteria are required to define an HIV infection that is well controlled: undetectable viral RNA load, CD4+ count \\>350, no history of AIDS-defining opportunistic infection within the past 12 months, and stable for at least 4 weeks on the same anti-HIV medications. If an HIV infection meets the above criteria, monitoring of viral RNA load and CD4+ count is recommended. Subjects/participants must be tested for HIV during the Screening Period if acceptable by local regulations or an IRB/IEC.\n* Has an active or uncontrolled hepatitis B and/or hepatitis C infection.\n* Has spinal cord compression or clinically active brain metastases, defined as untreated and symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms. Participants with clinically inactive brain metastases may be included in the study. A minimum of 2 weeks must have elapsed between the end of whole brain radiotherapy and study enrollment. Participants with treated brain metastases that are no longer symptomatic and who require no treatment with steroids may be included in the study if they have recovered from the acute toxic effect of radiotherapy.\n* Is lactating or pregnant as confirmed by pregnancy tests performed within 7 days before enrollment.\n* Has unresolved toxicities from previous anticancer therapy.\n* Has a concomitant medical condition that would increase the risk of toxicity, in the opinion of the Investigator.\n* Has a history of severe hypersensitivity reactions to either the drug substances or inactive ingredients of DS-1062a. Has a history of severe hypersensitivity reaction to other monoclonal antibodies.\n* Has any other medical conditions, including cardiac disease or psychological disorders, and/or substance abuse that would increase the safety risk to the participant or interfere with participation of the participant or evaluation of the clinical study in the opinion of the Investigator.\n* Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder, or any autoimmune, connective tissue or inflammatory disorders with pulmonary involvement, or prior pneumonectomy.\n* Has leptomeningeal carcinomatosis.\n* Has substance abuse or any other medical conditions such as clinically significant cardiac or psychological conditions, that may, in the opinion of the investigator, interfere with the participant's participation in the clinical study or evaluation of the clinical study results.\n* Psychological, social, familial, or geographical factors that would prevent regular follow-up. Adults under guardianship, curatorship, safeguard of justice, or family empowerment measure are not eligible.\n* Otherwise considered inappropriate for the study by the investigator.\n\nAdditional Exclusion Criteria for Sub-study:\n\n* Has had any prior oral mucositis/stomatitis that did not resolve within 3 months of signing the ICFs\n* Requires oral steroid or steroid nasal spray or inhaler for asthma, chronic obstructive pulmonary disease, or any other reason at the time of randomization\n* Requires immunosuppressive drugs at the time of randomization\n* Has oral inflammation or infections, including candidiasis (thrush) at the time of randomization\n* Has a history of severe hypersensitivity reactions or any other contraindication to steroids or other active principles or excipients of the mouthwash",
        "NCTId": "NCT03401385"
    },
    {
        "ExclusionCriteria": "* Patients must not have clinically significant cardiac disease.\n* Patients must not have known non-controlled CNS metastasis.\n* Patients must not have a history of \u2265 Grade 3 allergic reactions to mAb therapy as wellas known or suspected allergy or intolerance to any agent given during this study.\n* Patients must not have had major surgery within 4 weeks before first BA3021 administration.\n* Patients must not have had prior therapy with a conjugated or unconjugated auristatin derivative/vinca-binding site targeting payload.\n* Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C.\n* Patients must not be women who are pregnant or breast feeding.",
        "NCTId": "NCT03504488"
    },
    {
        "ExclusionCriteria": "* Prior history of invasive breast cancer\n* Stage IV (metastatic) breast cancer\n* Prior systemic therapy for treatment and prevention of breast cancer\n* Contraindication to MRI scan and/or allergy to intravenous contrast-gadolinium\n* Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137).\n* Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks. Note: Participants must have recovered from all AEs due to previous therapies to \u2264Grade 1 or baseline. Participants with \u2264Grade 2 neuropathy may be eligible. Note: If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment.\n* Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis.\n* Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Gu\u00e9rin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist\u00ae) are live attenuated vaccines and are not allowed.\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.\n* Has a known additional malignancy that is progressing or has required active treatment within the past X 3 years prior to screening. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or cervical carcinoma in situ are not excluded. Patients with prior ductal/lobular carcinoma in situ are not excluded if they were treated exclusively with mastectomy \\> 3 years prior to diagnosis of current breast cancer.\n* Has severe hypersensitivity (\u2265Grade 3) to pembrolizumab or olaparib and/or any of its excipients.\n* Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\n* Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\n* Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis\n* Severe infections within 4 weeks prior to initiation of study treatment, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia.\n* Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment.\n\n  a. Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or to prevent chronic obstructive pulmonary disease exacerbation) are eligible for the study.\n* Has a known history of Human Immunodeficiency Virus (HIV).\n* Has a known history of Hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] reactive) or known active Hepatitis C virus (defined as HCV RNA \\[qualitative\\] is detected) infection.\n* Has a known history of active TB Bacillus Tuberculosis.\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n* Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment.\n* A WOCBP who has a positive urine pregnancy test within 72 hours prior to study start. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n* Note: If 72 hours have elapsed between the screening pregnancy test and the performed and must be negative in order for subject to start receiving study medication.\n* Patients who have undergone hCG-stimulation for egg harvest as part of fertility preservation within 7 days before treatment initiation are permitted to receive treatment despite a positive pregnancy test.",
        "NCTId": "NCT05203445"
    },
    {
        "ExclusionCriteria": "* Three or greater prior lines of therapy for metastatic TNBC\n* Known primary brain malignancy, brain metastases or active CNS pathology, any of which as determined by the Investigator\n* Currently participating in a study of an investigational agent\n* Body mass index \\< 18.5 kg/m2\n* Known hypersensitivity to SDX-7320 or eribulin\n* Established diagnosis of diabetes mellitus type I or uncontrolled or insulin-dependent type II. Uncontrolled is defined as fasting blood glucose \\>140 mg/dL and/or HbA1c \u22658%\n* Use of combination antihyperglycemic therapy (single agent metformin on stable dose for at least 3 months prior to enrollment is allowable)\n* Child Pugh score of B or C.\n* Concurrent malignancy or malignancy within 3 years of randomization, with the exception of adequately treated, basal or squamous cell carcinoma, nonmelanomatous skin cancer or curatively resected cervical cancer.\n* Uncontrolled human immunodeficiency virus (HIV) infection. (Testing is not mandatory.)\n* Evidence of uncontrolled active Hepatitis B or C infection\n* History of Stevens-Johnson Syndrome (SJS), erythema multiforme (EM), toxic epidermal necrolysis (TEN), or other severe medication-related cutaneous reactions.\n* Any other concurrent severe and/or uncontrolled medical condition that would, in the Investigator's judgment, contraindicate patient participation in the clinical study (e.g., chronic active hepatitis, severe hepatic impairment).\n* Clinically significant, uncontrolled heart disease and/or recent cardiac events including any of the following:\n\n  * History of angina pectoris, coronary artery bypass graft (CABG) symptomatic pericarditis, or myocardial infarction within 6 months prior to study entry.\n  * History of documented congestive heart failure (New York Heart Association functional classification III-IV).\n  * Documented cardiomyopathy.\n  * Left ventricular ejection fraction (LVEF) \\<45%, as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO).\n  * History of any cardiac arrhythmias, (e.g., ventricular tachycardia), complete left bundle block, high grade atrioventricular (AV) block (e.g., bifascicular block, Mobitz type II and third-degree AV block) supraventricular, nodal arrhythmias, or conduction abnormality in the previous 12 months.\n  * Uncontrolled hypertension, defined by a systolic blood pressure (SBP) \u2265160 mmHg and/or diastolic blood pressure (DBP) \u2265100 mmHg, with or without antihypertensive medication. Initiation or adjustment of antihypertensive medication(s) is allowed prior to screening\n  * Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome or any of the following: risk factors for torsades de pointe including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure or history of clinically significant/symptomatic bradycardia; concomitant medications with a known risk to prolong the QT interval and known to cause torsades de pointe that cannot be discontinued or replaced by safe alternative medications.\n  * Bradycardia (heart rate less than 50 at rest), by electrocardiogram (ECG) or pulse.\n  * Inability to determine the QT interval on the ECG (i.e., unreadable or not interpretable) or corrected QT (QTcF) \\>450 msec for males and \\>470 msec for females (using Fridericia's correction) during Screening, based on the mean of triplicate ECGs\n* Currently receiving any of the following medications and cannot be discontinued 7 days prior to the start of the treatment: Medications with a known risk to prolong the QT interval or induce Torsade de Pointes (TdP). CredibleMeds list of drugs known to cause TdP may be used as a reference for this study to determine which drugs are prohibited using the following link: https://crediblemeds.org/new-drug-list or a crediblemeds mobile application.\n\n  \u00b0Herbal preparations/medications, with the exception of cannabinoids, CBD compounds, etc.\n* Participation in a prior investigational study within 14 days prior to the start of the study treatment or within 5 half-lives of study drug, whichever is longer.\n* History of acute pancreatitis within 1 year of Screening or past medical history of chronic pancreatitis\n* Pregnant patients",
        "NCTId": "NCT05570253"
    },
    {
        "ExclusionCriteria": "* Prior treatment with any adoptive T-cell therapy or anti-ROR1 therapy\n* Prior solid organ transplantation\n* Active, untreated brain metastasis or leptomeningeal disease; stable, treated brain involvement by disease is allowed\n* Untreated or active infection at the time of screening or leukapheresis\n* HIV-positive, HTLV-1-positive, active acute or chronic HBV or HCV, or active tuberculosis\n* Impaired cardiac function or clinically significant cardiac disease\n* Uncontrolled pleural or pericardial effusion\n* Systemic corticosteroids or other immunosuppressive medications within 14 days of leukapheresis\n* Required chronic anticoagulation, such as warfarin, low molecular weight heparin, or Factor Xa inhibitors\n* Pregnant or lactating/nursing women",
        "NCTId": "NCT05274451"
    },
    {
        "ExclusionCriteria": "* Multifocal disease\n* Clinically N1 disease at diagnosis\n* Invasive lobular carcinoma\n* Metastatic disease\n* Patients for whom RT would be contraindicated (e.g., connective tissue disorder or prior ipsilateral breast radiation)\n* Patients with known BRCA1/2 mutations\n* Pregnant or nursing",
        "NCTId": "NCT03165487"
    },
    {
        "ExclusionCriteria": "* Stage IV (metastatic) breast cancer as well as history of any prior (ipsi- or contralateral) invasive breast cancer.\n* Prior treatment with another stimulatory or coinhibitory T-cell receptor agent (eg, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), OX-40, cluster of differentiation 137 (CD137), prior treatment with any HER2-directed agent, prior or concurrent treatment with any endocrine therapy agent.\n* Evidence of recurrent disease following preoperative therapy and surgery.\n* Prior treatment with topoisomerase 1 inhibitors or antibody-drug conjugates (ADCs) containing a topoisomerase inhibitor.\n* Individuals with germline breast cancer gene (BRCA) mutations.\n* Myocardial infarction or unstable angina pectoris within 6 months of enrollment or history of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias or Left ventricular ejection fraction (LVEF) of \\< 50%\n* Active serious infections requiring anti-microbial therapy.\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
        "NCTId": "NCT05633654"
    }
]